Transpara Showcases Innovative FDA-Cleared Breast AI Capabilities
AI-Powered Mammography Enhancements to be Showcased at SBI Symposium
Table of Contents
- AI-Powered Mammography Enhancements to be Showcased at SBI Symposium
- AI-Powered Mammography: A Q&A on the Latest Advancements
- What’s new in AI-powered mammography?
- What is transpara and what does it do?
- What is transpara 2.1?
- How does comparing with prior exams help in breast cancer detection?
- Has transpara 2.1 received regulatory approval?
- what clinical benefits of transpara will be highlighted at the SBI Symposium?
- What specific studies and presentations will be featured at the SBI Symposium?
- what is the potential impact of transpara Risk?
- How has transpara performed in real-world screening settings?
- What is ScreenPoint Medical’s mission?
- Key Benefits of transpara – Speedy Summary
COLORADO SPRINGS, Colo.
– ScreenPoint Medical is set to present the latest advancements in its Breast AI, transpara, at the Society of Breast Imaging (SBI) Symposium from April 24-27. Transpara,designed to aid radiologists in earlier cancer detection and reduce recall rates,is promoted as the most clinically validated AI in its field.
Transpara 2.1: Refining Breast Cancer Detection
ScreenPoint Medical will feature Transpara 2.1, an updated algorithm designed to improve breast cancer detection. The new version includes compatibility with breast density assessments and allows for comparison with prior exams.
This temporal comparison capability enables analysis of suspicious areas against up to three prior exams spanning six years. Transpara 2.1 has received both CE marking and FDA clearance.
“We are excited about the notable betterment of Transpara performance when priors are used, especially when more priors with a longer time interval are included, which is in line with radiologists’ experience,” said Professor Nico Karssemeijer, PhD, co-founder and Chief Scientific Officer of ScreenPoint Medical. “Our solution is designed for screening and diagnostic use to truly improve clinical workflow.”
SBI Presentations highlight Clinical Benefits
several presentations at the SBI symposium will focus on the clinical advantages of Transpara in enhancing mammography screening. Alejandro Rodriguez Ruiz, PhD, and Dr. Rachel F. Brem are among those scheduled to present.
-
Validation of a Novel Image-based AI Breast Cancer Risk Model for Mammography Screening: A study validating Transpara Risk, an AI model for breast cancer risk assessment, will be presented , from 2:45 – 3:45 PM. The study suggests the model’s performance could support personalized screening strategies by identifying women who may benefit from supplemental imaging.
- Multi-site Validation of a Novel AI System for Cancer Detection in Abbreviated Breast MRI: Another study, also on from 2:45 – 3:45 PM, validates AI performance in detecting breast cancer using abbreviated DCE-MRI across multiple institutions. Results indicate potential for decision support, particularly in identifying normal exams.
-
Practical and Pro Tips for Incorporating AI into Your Practice: Dr. Rachel F. Brem, director of Breast Imaging and Imaging at George Washington University, will discuss AI implementation in breast clinical practice on , from 9:15 – 9:40 AM.
Real-World Impact of Transpara
Transpara has been evaluated in multiple large-scale screening populations, including those in Denmark, Sweden, and Norway. The MASAI trial,published in The Lancet digital Health,showed a 29% increase in cancer detection and a 44% reduction in radiologists’ workload when using Transpara.
About ScreenPoint Medical
ScreenPoint Medical focuses on translating machine learning research into accessible technology for radiologists, with the goal of improving screening workflow, decision confidence, and breast cancer risk assessment.
AI-Powered Mammography: A Q&A on the Latest Advancements
What’s new in AI-powered mammography?
AI is rapidly transforming mammography, and ScreenPoint Medical is at the forefront with its Breast AI, transpara. The latest advancements will be showcased at the Society of Breast Imaging (SBI) Symposium from april 24-27, 2025, in Colorado Springs, Colorado. Transpara is designed to help radiologists detect breast cancer earlier and reduce the need for repeat screenings (recall rates).It’s promoted as the most clinically validated AI in its field.
What is transpara and what does it do?
Transpara is an AI-powered tool designed to assist radiologists in analyzing mammograms.It uses advanced algorithms to identify potential anomalies and provide a second opinion, which can lead to earlier cancer detection and reduce the number of needless recalls.
What is transpara 2.1?
Transpara 2.1 is the updated version of ScreenPoint Medical’s algorithm. This version includes improvements to enhance breast cancer detection capabilities. it has been designed to be compatible with breast density assessments and allows for comparison with previous mammogram exams (priors).
How does comparing with prior exams help in breast cancer detection?
The ability to compare current mammograms with up to three previous exams spanning six years is a key feature.This “temporal comparison” allows radiologists to analyse any suspicious areas against historical data. This temporal comparison is very vital, as stated by Professor Nico Karssemeijer, PhD, co-founder and Chief Scientific Officer of ScreenPoint Medical, as it aligns with the experience of radiologists.
Has transpara 2.1 received regulatory approval?
Yes, transpara 2.1 has received both CE marking and FDA clearance, meaning it meets the necessary safety and efficacy standards for use in clinical settings.
what clinical benefits of transpara will be highlighted at the SBI Symposium?
several presentations at the SBI symposium will discuss how transpara enhances mammography screening. These presentations will cover clinical advantages, including improved cancer detection and workflow efficiency.
What specific studies and presentations will be featured at the SBI Symposium?
several studies will be presented at the SBI symposium, focusing on the clinical advantages of transpara. Here’s a summary:
Validation of a Novel Image-based AI Breast Cancer Risk Model for Mammography Screening: This study validates Transpara Risk, an AI model for assessing breast cancer risk.(Thursday, April 24, 2:45 – 3:45 PM)
Multi-site Validation of a Novel AI System for Cancer Detection in abbreviated Breast MRI: This study validates AI’s role in detecting breast cancer using abbreviated DCE-MRI across multiple institutions. (Thursday, april 24, 2:45 – 3:45 PM)
Practical and Pro Tips for Incorporating AI into Your Practise: Rachel F. Brem, MD, will discuss the practical aspects of integrating AI into breast imaging practice. (Saturday, April 26, 9:15 – 9:40 AM)
what is the potential impact of transpara Risk?
The study validating Transpara Risk suggests that the model can help personalize screening strategies by identifying women who may benefit from supplemental imaging.
How has transpara performed in real-world screening settings?
Transpara has been evaluated in large-scale screening populations in Denmark, Sweden, and Norway. The MASAI trial, published in The Lancet Digital Health, showed a significant impact: a 29% increase in cancer detection and a 44% reduction in the workload of radiologists.
What is ScreenPoint Medical’s mission?
ScreenPoint Medical focuses on translating machine learning research into practical technology for radiologists. Their goal is to improve the screening workflow, increase decision confidence, and aid in breast cancer risk assessment.
Key Benefits of transpara – Speedy Summary
Here’s a quick overview of the benefits of transpara:
| Feature | Benefit |
| —————————- | —————————————————————————- |
| AI-Powered Analysis | Enhances breast cancer detection |
| Integration with Prior Exams | Enables temporal comparison for more extensive analysis |
| Reduced Radiologist Workload | Potential to increase efficiency and reduce the number of recalls. |
| FDA Clearance and CE marking | Meets regulatory standards for safety and effectiveness |
| Risk Assessment | The Transpara Risk* model assists in personalizing breast cancer screening.|